Fundraising Fox

Amylyx

NASDAQ: AMLXUnicorn · $2.1B

Cambridge, US · Founded 2014 · 3 known investors

Find your way into Amylyx

379 people in our graph share verified history with the Amylyx team — schools, employers, funds. One of them is your warm intro.

Dylan Fieldunlockedknows Joshua Cohen · together at Brown University (overlapped)
×6knows the team · via Massachusetts General Hospital/Harvard Medical School
×3knows the team · via Brown University
×2knows the team · via Milton Academy

Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.

BiotechHealthtech

Founders & leadership

Amylyx was founded in 2014 by Justin Klee and Joshua Cohen.

JK
Justin KleeinCo-Founder & Co-CEOJustin Klee is director at Amylyx Pharmaceuticals, a publicly traded company developing therapies for neurodegenerative and endocrine diseases including amyotrophic lateral sclerosis and Wolfram syndrome.
JCJoshua Cohen
Joshua CoheninCo-Founder and Co-CEO at Amylyx PharmaceuticalsJoshua Cohen is co-founder of Amylyx Pharmaceuticals, a biopharmaceutical company developing therapies for rare neurodegenerative and endocrine diseases including ALS, congenital hyperinsulinism, and Wolfram syndrome. He has led the company in developing and commercializing medicines for rare disease indications.
PB
Peter B. FinnSecretary

Board

SD
Stephen D. ChubbBoard director
GM
George M. Milne, PH.D.Board director

Investors · 3

Alpha Wave GlobalMiami
Avoro Capital AdvisorsNew York
Bain Capital Life SciencesBoston

Reported raises · per SEC filings

Form D private placements

$65.1M disclosed across 6 rounds · 2014–2020

▶$30MraisedJul 2020 · 17 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen ChubbDirector
  • Justin KleeExecutive Officer, Director
  • Isaac ChengDirector
  • Peter FinnExecutive Officer
  • George MilneDirector
  • Joshua CohenExecutive Officer, Director
  • Walter GilbertDirector
  • Felix Von CoerperDirector
Offering amount
$30M
Amount sold
$30M
Minimum investment
$10K
First sale
Jun 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.8MraisedJan 2020 · 37 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Justin KleeExecutive Officer, Director
  • Joshua CohenExecutive Officer, Director
  • Stephen ChubbDirector
  • George MilneDirector
  • Peter FinnExecutive Officer
  • Walter GilbertDirector
  • Isaac ChengDirector
  • Felix Von CoerperDirector
Offering amount
$20M
Amount sold
$14.8M
Minimum investment
$10K
Proceeds to insiders
$360K
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13MraisedNov 2018 · 32 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Felix Von CoerperDirector
  • George MilneDirector
  • Peter FinnExecutive Officer
  • Walter GilbertDirector
  • Justin KleeExecutive Officer, Director
  • Joshua CohenExecutive Officer, Director
  • Stephen ChubbDirector
  • Isaac ChengDirector
Offering amount
$13M
Amount sold
$13M
Minimum investment
$10K
Proceeds to insiders
$360K
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedAug 2017 · 30 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Isaac ChengDirector
  • Joshua CohenExecutive Officer, Director
  • Justin KleeExecutive Officer, Director
  • Stephen ChubbDirector
  • Peter FinnExecutive Officer
  • George MilneDirector
  • Walter GilbertDirector
  • Felix Von CoerperDirector
Offering amount
$2.3M
Amount sold
$1.8M
Minimum investment
$2.4K
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedAug 2016 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George MilneDirector
  • Peter FinnExecutive Officer
  • Stephen ChubbDirector
  • Joshua CohenExecutive Officer, Director
  • Justin KleeExecutive Officer, Director
Offering amount
$5M
Amount sold
$4.1M
Minimum investment
$15K
Proceeds to insiders
$620K
First sale
Aug 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.4MraisedNov 2015 · 28 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Stephen D. ChubbDirector
  • Joshua CohenExecutive Officer, Director
  • George M. Milne, PH.D.Director
  • Peter B. FinnExecutive Officer
  • Justin KleeDirector
Offering amount
$1.6M
Amount sold
$1.4M
Minimum investment
$10K
Proceeds to insiders
$75K
First sale
Mar 2014
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$2.1Bvaluation at IPOOct 2022 · $32.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Amylyx went on to found or lead other companies.

Joshua CohenFounderFounded AmylyxJustin KleeCo-Founder & Co-CEOFounded Amylyx

In the news

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | The Motley Foolfool.com · Sep 2026Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? - AOLaol.com · Sep 2026Guggenheim raises Amylyx stock price target on financing, trial data By Investing.cominvesting.com · Aug 2026Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week | The Motley Foolfool.com · Aug 2026Amylyx Raises $500 Million to Advance Avexitide After Positive Phase 3 PBH Results | BioPharm Internationalbiopharminternational.com · Aug 2026Guggenheim raises Amylyx stock price target on trial results By Investing.cominvesting.com · Aug 2026Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raisefinance.yahoo.com · Aug 2026Amylyx moves to raise USD 350m after avexitide's Phase III hypoglycemia winallsci.com · Aug 2026

Frequently asked questions

What does Amylyx do?
Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs. It focuses on solving difficult medical challenges for affected patients and their families.
Who founded Amylyx?
Amylyx was founded by Justin Klee, Joshua Cohen in 2014.
Who are Amylyx's investors?
Amylyx's investors include Alpha Wave Global, Avoro Capital Advisors, Bain Capital Life Sciences.
How much funding has Amylyx raised?
Amylyx has disclosed $65.1M raised across 6 rounds.
Where is Amylyx headquartered?
Amylyx is headquartered in Cambridge, US.